A Phase Ib Study of Varlitinib in Japanese Subjects With Advanced or Metastatic Solid Tumours
Phase of Trial: Phase I
Latest Information Update: 02 Jan 2019
At a glance
- Drugs Capecitabine (Primary) ; Varlitinib (Primary)
- Indications Biliary cancer; Carcinoma; Cholangiocarcinoma; Gallbladder cancer; Solid tumours
- Focus Adverse reactions
- Sponsors ASLAN Pharmaceuticals
- 02 Jan 2019 According to an ASLAN Pharmaceuticals media release, Varlitinib has demonstrated tumour shrinkage responses and durable disease stabilization in BTC patients in this phase 1b study.
- 27 Jun 2018 Status changed from active, no longer recruiting to completed.
- 08 Jan 2018 Status changed from recruiting to active, no longer recruiting.